- Join Us
- About the Event
- About CRI
- Why Immunotherapy
I lost my family member to cancer recently. They lost their battle far too soon due to this devastating disease. My unwavering commitment to this cause has only strengthened as a result of this tragic loss.
I could not be more proud to raise money for this incredible charity which not only works at finding a cure for all cancers, but also works at building a community of people who have been affected themselves by cancer, or have loved ones affected by this horrible disease. I truly believe we can make a difference. Together we can fund research, provide hope and stay on a relentless pursuit to save people's lives. Nobody should have to watch their family or friends die from cancer ever again.
Two years ago, I rode in my first charity cycling event--a 2 day, 150 mile ride throughout upstate New York and parts of Connecticut. Last year, I participated in the first annual Answer to Cancer bike ride. This year, as I gear up for round 3, I ask that you kindly help me meet and exceed my fundraising goal of $10,000. No donation is too big or too small.
Cancer can affect anyone, which is why I am proud to be participating in this event that will help create the Answer to Cancer. The Cancer Research Institute is working hard to bring a new and promising way to treat cancer, called immunotherapy, to all cancer patients.
Please make a donation today to help me reach my fundraising goal. 100% of all donations will go to support lifesaving cancer research.
I am grateful for your donations and for your help in spreading the word. Together, we will find the Answer to Cancer!
Stephen, diagnosed with metastatic colorectal cancer at 28, enrolled in a clinical trial for a checkpoint inhibitor, a type of immunotherapy.
Read Stephen's Story
Deborah, who was treated with the immunotherapy Yervoy" in combination with radiation for stage III melanoma, participated in the 2016 Answer to Cancer cycling event to raise funds for CRI.
Read Deborah's Story
In 2012, life-long Tennessean Philip was shocked to learn that he had kidney cancer. Not satisfied with the chemotherapy options presented to him, Philip enrolled a clinical trial for the immunotherapy nivolumab (Opdivo").
Read Philip's Story